VIGL
Closed
Vigil Neuroscience Inc
2.4
-0.1 (-4.00%)
Last Update: 10 Mar 2025 23:00:00
Yesterday: 2.5
Day's Range: 2.26 - 2.545
Send
sign up or login to leave a comment!
When Written:
10.04
Vigil Neuroscience Inc is a biotechnology company that focuses on developing innovative treatments for neurological disorders. The company was founded in 2019 and is headquartered in Montreal, Canada.
Vigil Neuroscience Inc's main area of focus is on developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company's approach involves targeting the immune system to prevent or slow down the progression of these diseases.
The company's lead product candidate is VGL-01, a small molecule drug that targets the immune system to protect neurons from damage and inflammation. VGL-01 is currently in preclinical development and has shown promising results in animal models of Alzheimer's disease.
Vigil Neuroscience Inc is backed by several investors, including AmorChem, a Canadian venture capital firm that specializes in life sciences investments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Vigil Neuroscience Inc's main area of focus is on developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company's approach involves targeting the immune system to prevent or slow down the progression of these diseases.
The company's lead product candidate is VGL-01, a small molecule drug that targets the immune system to protect neurons from damage and inflammation. VGL-01 is currently in preclinical development and has shown promising results in animal models of Alzheimer's disease.
Vigil Neuroscience Inc is backed by several investors, including AmorChem, a Canadian venture capital firm that specializes in life sciences investments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!